Drug Approval | June 10, 2022
Sanofi Dupixent gets USFDA nod for atopic dermatitis
Dupixent is the first and only biologic medicine approved to treat moderate-to-severe atopic dermatitis from infancy to adulthood
Dupixent is the first and only biologic medicine approved to treat moderate-to-severe atopic dermatitis from infancy to adulthood
Futnani has over two decades of experience in delivering growth and transformation that spans several therapeutic areas.
Foundation S will incorporate as its cornerstone initiative the former Sanofi Espoir Foundation’s ‘My Child Matters’ program in childhood cancer
Business EPS of €1.94, up 20.5% on a reported basis and 16.1% at CER, also benefitting from an improved effective tax rate
Beyond the technical leadership from F1, the collaboration will bring a specific focus on the people dimension of high performance
Terran to advance the development of two of Sanofi's Phase 3 CNS therapeutics
Rodolfo brings with him a wealth of rich experience from commercial, marketing, and general management roles across several multinational companies
Sanofi’s DE&I Board will include three of the most influential voices in the DE&I space as Board members appointed for 3 years: organizational psychologist & best-selling author John Amaechi, award-winning social entrepreneur Caroline Casey, and DE&I pioneer and renowned thought-leader Dr. Rohini Anand
Companies to leverage proprietary IgM antibody technology platform to discover agonists against three oncology targets and three immunology/inflammation targets
Dupixent peak sales ambition raised to more than €13 billion
Subscribe To Our Newsletter & Stay Updated
